Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia

Next Previous
Trial Profile

Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors FUJIFILM Toyama Chemical

    • Most Recent Events

    • 16 Oct 2020 According to an FUJIFILM Toyama Chemical media release, the company has filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan Tablet to the Ministry of Health, Labour and Welfare in Japan to add an indication as well as dosage and administration concerning COVID-19 to the current manufacturing and marketing approval items of Avigan, based on data from this trial.
    • 23 Sep 2020 Results published in FUJIFILM Toyama Chemical Media Release.
    • 23 Sep 2020 According to an FUJIFILM Toyama Chemical media release, the company will conduct a detailed analysis of the data obtained from this study in as early as October.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top